Tests an AI tool on heart ECGs to spot transthyretin cardiac amyloidosis
Tests an AI platform reading heart tracings to detect cardiac amyloidosis in adults.
Plain-language title generated from the registry record
Registry title: Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Key facts
- Where
- Toulouse, FranceSee the site
Where in France
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Idoven 1903 S.L.
- Trial code
- NCT06978660
- Record updated
- 4 November 2026
- Original description
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.Read full original descriptionShow less
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (CONCERTO)
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.
Inclusion: Subjects ≥ 18 years old; Subjects with 12-leads ECG records with a 10 seconds minimum length on digital format.
Exclusion: Patients with paced rhythm on the ECG.